Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
KR -  Seoul
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand

North America

US -  San Francisco
US -  Boston

GLOBAL

English

SOLUTIONS

RESOURCES

ABOUT US

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
KR -  Seoul
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand

North America

US -  San Francisco
US -  Boston

GLOBAL

English

The Strategic Opportunity: ‘Running First-in-human and Vaccine Studies in Australia’ - Novotech Webinar

The Strategic Opportunity: ‘Running First-in-human and Vaccine Studies in Australia’ - Novotech Webinar

July 23,2020

The leading Asia-Pacific biotech specialist CRO Novotech is collaborating with biotech and pharma news platform Endpoints News for a webinar about the strategic and quality benefits of running first-in-human vaccine studies in Australia.

Novotech has conducted over 500 early phase clinical trials for biotech companies.

According to Novotech:

“The regulatory environment in Australia offers a significant strategic opportunity for international biotech companies who can take advantage of a uniquely fast and pragmatic regulatory pathway for early phase clinical trials.

A US Investigational New Drug (IND) submission is not necessary to initiate first-in-human clinical trials in Australia.

The rapid Australian and New Zealand regulatory and ethics processes often means biotech companies can initiate their clinical programs and commence dosing within a single review cycle of 6-8 weeks from submission.

As a result, many biotechnology companies can commence a first-in-human clinical trial in parallel to the preparation of a US IND submission.”

During this webinar, experts will discuss:

  • The latest research and trends of early phase clinical trials globally and in Asia-Pacific, with a focus on vaccine studies
  • How the Australian regulatory requirement compares with the US, and what are the benefits for biotechnology companies to involve sites in Australia
  • How to take advantage of the Australian R&D Government refund (of up to 43.5%)
  • Feedback from sponsors and investigators

The webinar will be led by Endpoints News Publisher Arsalan Arif. Participants will include leading experts from the Australian clinical trial sector:

  • Dr. Paul Griffin, Principal Investigator at Nucleus Network
  • Dr. Jeff Loutit, Chief Medical Officer at Qpex Biopharma
  • Dr. Simone Flight, Senior Consultant at Novotech Biodesk
  • Stewart Walker, President, CoSec USA

Webinar: Running First-in-human and Vaccine Studies in Australia

Broadcast time: August 11, 2-3pm EDT

Click here to register

Novotech has teams on the ground in the key Asia-Pacific countries and has just signed its 30th Partnership agreement which is a program with leading medical institutions throughout the Asia-Pacific giving Novotech clients unique access to some of the top researchers, investigators and key opinion leaders.